View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 23, 2020updated 12 Jul 2022 11:44am

Evelo Biosciences to study Covid-19 drug in TACTIC-E trial

Evelo Biosciences has announced the inclusion of its experimental drug candidate, EDP1815, in the Phase II/III TACTIC-E clinical trial being conducted in the UK.

Evelo Biosciences has announced the inclusion of its experimental drug candidate, EDP1815, in the Phase II/III TACTIC-E clinical trial being conducted in the UK.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial is intended to assess the safety and efficacy of some investigational therapies for preventing and treating complications caused by Covid-19 in hospitalised patients at the early stages of the infection.

TACTIC-E is led by Dr Joseph Cheriyan from Addenbrooke’s Hospital in Cambridge, UK, with Cambridge University Hospitals NHS Foundation Trust sponsoring the study.

According to results from a Phase Ib trial in psoriasis patients, EDP1815 could regulate different immune pathways related to cytokine storm and resolve the inflammation without immunosuppression.

TACTIC-E will enrol up to 469 patients per arm at multiple clinical centres across the UK.

The trial will recruit patients with identified risk factors for developing severe complications and who are at risk of progression to the intensive care unit or death.

Participants will be given EDP1815 or a ambrisentan and dapagliflozin combination, with standard of care, or standard of care alone.

The primary outcome measure is a decrease in the number of patients developing severe complications of organ failure, ventilation or death, while secondary outcomes include duration of hospital stay and oxygen therapy, changes in Covid-19 progression biomarkers, and time to clinical improvement.

Interim results are expected to be available during the fourth quarter of this year. If positive data is obtained, Evelo plans to hold discussions with regulatory agencies for potential registration.

Evelo Biosciences chief scientific officer Mark Bodmer said: “EDP1815 has the potential to address the complex inflammatory chaos associated with cytokine storm in Covid-19 without immunosuppression.

“EDP1815’s mechanism of action may make it suitable for early intervention in Covid-19 patients who have not yet been shown to benefit from anti-inflammatory therapy.”

If the drug candidate secures approval to treat Covid-19, Evelo can rapidly scale its manufacturing and provide it at an affordable cost.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena